Results 131 to 140 of about 121,164 (262)

Low effectiveness of influenza vaccines vis-à-vis mechanism of protection by vaccines - potential causes and recommendations to improve control of influenza. [PDF]

Front Immunol
Gupta RK, Alugupalli KR, Cowell JL.
europepmc   +1 more source

Mitigating Health Disparities Through Empathetic Policymaking During Times of Crisis

Public Administration and Development, EarlyView.
ABSTRACT The COVID‐19 pandemic greatly exacerbated the existing disparities and inequities in health and healthcare among historically marginalized populations. Today, these impacts still echo. These persistent structured inequities erode the public's trust in government, lead to failure in public policies, and result in worse health consequences ...
Yali Pang, Brittany Keegan, Robyn D. McDougle   +2 more
wiley   +1 more source

Nudges to Clinicians and Patients for Influenza Vaccines During Visits: The BE IMMUNE Randomized Clinical Trial. [PDF]

JAMA Intern Med
Mehta SJ, Waddell KJ, Linn KA, Brophy C, Liang J, Park SH, Reitz C, Williams K, Couzens C, Staloff J, White AA, Rhodes C, Liao JM, Navathe AS.   +13 more
europepmc   +1 more source

Enterovirus infections in children

Pediatric Investigation, EarlyView.
Enteroviruses (EVs) are major pathogens causing a wide spectrum of diseases in children worldwide. This review summarizes the epidemiology, virology, viral replication, and virus‐host interactions of EVs. It also highlights current advances in clinical diagnosis, antiviral therapies, and vaccine development, providing insights into future strategies ...
Xiangpeng Chen, Lingyun Guo, Xiaobo Lei, Linqing Zhao, Mingyan Hei, Jun Shen, Ju Yin, Fei Li, Jikui Deng, Gang Liu, Yong Zhang, Zhengde Xie   +11 more
wiley   +1 more source

Chronic Diseases and Influenza Vaccines. [PDF]

Vaccines (Basel)
Lian R, Zhang H, An Y, Chen Z.
europepmc   +1 more source

Infection risk in rheumatoid arthritis patients treated with biologic and targeted therapies

Rheumatology &Autoimmunity, EarlyView.
In this context, infections associated with each biologic and targeted drug are summarized to inform the stratification of RA patients, including the characteristics of the susceptible patients and their concomitant therapy. We aim to provide a benefit‐risk analysis for clinical decision, and vital indications for the prevention of highly correlated ...
Lujing Wang, Jieshi Lin, Jie Qian
wiley   +1 more source

Lysosome-targeting live attenuated influenza vaccines elicit robust and broad immunity in mice. [PDF]

Nat Commun
Hao J, Wang P, Shen Q, Xi X, Tong L, Hou J, Li L, Wang Q, Liu C, Li J, Zhao H, Zhang Q, Plebani R, Chou D, Zhang L, Zhou D, Si L.   +16 more
europepmc   +1 more source

Driving Drugs Deeper: Force‐Driven Microneedle Systems for Active Therapy and Their Road Towards Clinical Implementation

Small, EarlyView.
Force‐driven microneedles are presented as active therapeutic microdevices that overcome the diffusion limits of conventional patches. By integrating gas generation, magnetic actuation, cavitation, or iontophoresis, these systems drive payloads deeper into tissue, enabling faster, more controlled delivery and highlighting key design principles and ...
Majed Amini, Phoebe Li, Hamed Shahsavan, Mahla Poudineh   +3 more
wiley   +1 more source

Effectiveness of Influenza Vaccines in Italy in the 2024/2025 Season: A Nationwide, Test-Negative Design Study Based on Surveillance Records. [PDF]

Influenza Other Respir Viruses
Cifo D, Mateo-Urdiales A, Puzelli S, Facchini M, Piacentini S, Giombini E, Bellini B, Fabiani M, Pezzotti P, Stefanelli P, Palamara AT, Bella A, RespiVirNet network.   +12 more
europepmc   +1 more source

Applications of chitosan derivatives as adjuvants for nanoparticle‐based vaccines: A comprehensive review

Smart Molecules, EarlyView.
This review highlights how chitosan derivatives enhance nanoparticle‐based vaccines through superior stability, mucoadhesion, and immune modulation. By triggering robust mucosal, humoral, and cellular responses, these biocompatible polymers serve as a transformative platform for next‐generation immunotherapeutics and safe and effective vaccine delivery
Sayantani Dasgupta, Susanta Paul, Swarupananda Mukherjee, Nilanjan Sarkar, Arvind Kumar, Amrita Chakraborty, Anannya Bose, Atanu Hazra, Mainak Chakraborty   +8 more
wiley   +1 more source